Responsible Opioid Prescribing In Chronic Non-Cancer Pain: Part 2 - Guidance
Publication Date: July 1, 2012
Last Updated: March 14, 2022
Recommendations
Part 2 of the guidelines on responsible opioid prescribing provides the following recommendations for initiating and maintaining chronic opioid therapy of 90 days or longer
Initial Steps of Opioid Therapy
Comprehensive assessment and documentation is recommended before initiating opioid therapy, including documentation of comprehensive history, general medical condition, psychosocial history, psychiatric status, and substance use history. (G)
324002
Despite limited evidence for reliability and accuracy, screening for opioid use is recommended, as it will identify opioid abusers and reduce opioid abuse. (L)
324002
Prescription monitoring programs must be implemented, as they provide data on patterns of prescription usage, reduce prescription drug abuse or doctor shopping. ()
(Evidence: good to fair)
324002
Urine drug testing (UDT) must be implemented from initiation along with subsequent adherence monitoring to decrease prescription drug abuse or illicit drug use when patients are in chronic pain management therapy. (G)
324002
Establishing Diagnosis
Establish appropriate physical diagnosis and psychological diagnosis if available prior to initiating opioid therapy. (G)
324002
Caution must be exercised in ordering various imaging and other evaluations, interpretation and communication with the patient; to avoid increased fear, activity restriction, requests for increased opioids, and maladaptive behaviors. (G)
324002
Stratify patients into one of the 3 risk categories – low, medium, or high risk. ()
324002
A pain management consultation, may assist non-pain physicians, if high-dose opioid therapy is utilized. (F)
324002
Establishing Medical Necessity
Essential to establish medical necessity prior to initiation or maintenance of opioid therapy. (G)
324002
Establishing Treatment Goals
Establish treatment goals of opioid therapy with regard to pain relief and improvement in function. (G)
324002
Assessment of Effectiveness of Opioid Therapy
Long-acting opioids in high doses are recommended only in specific circumstances with severe intractable pain that is not amenable to short-acting or moderate doses of long-acting opioids, as there is no significant difference between long-acting and short-acting opioids for their effectiveness or adverse effects. (F)
324002
The relative and absolute contraindications to opioid use in chronic non-cancer pain must be evaluated including respiratory instability, acute psychiatric instability, uncontrolled suicide risk, active or history of alcohol or substance abuse, confirmed allergy to opioid agents, coadministration of drugs capable of inducing life-limiting drug interaction, concomitant use of benzodiazepines, active diversion of controlled substances, and concomitant use of heavy doses of central nervous system depressants. ()
(Evidence: fair to limited)
324002
Informed Decision-Making
A robust agreement which is followed by all parties is essential in initiating and maintaining opioid therapy as such agreements reduce overuse, misuse, abuse, and diversion. (F)
324002
Initial Treatment
Once medical necessity is established, opioid therapy may be initiated with low doses and short-acting drugs with appropriate monitoring to provide effective relief and avoid side effects. ()
(Evidence: fair for short-term effectiveness, limited for long-term effectiveness)
324002
Up to 40 mg of morphine equivalent is considered as low dose, 41 to 90 mg of morphine equivalent as a moderate dose, and greater than 91 mg of morphine equivalence as high dose. (F)
324002
In reference to long-acting opioids, titration must be carried out with caution and overdose and misuse must be avoided. (G)
324002
Adherence Monitoring
Methadone is recommended for use in late stages after failure of other opioid therapy and only by clinicians with specific training in the risks and uses. (L)
324002
Monitoring recommendation for methadone prescription is that an electrocardiogram should be obtained prior to initiation, at 30 days and yearly thereafter. (F)
324002
Monitoring and Managing Side Effects
In order to reduce prescription drug abuse and doctor shopping, adherence monitoring by UDT and PMDPs provide evidence that is essential to the identification of those patients who are non-compliant or abusing prescription drugs or illicit drugs. (F)
324002
Constipation must be closely monitored and a bowel regimen be initiated as soon as deemed necessary. (G)
324002
The Final Phase
Chronic opioid therapy may be continued, with continuous adherence monitoring, in well-selected populations, in conjunction with or after failure of other modalities of treatments with improvement in physical and functional status and minimal adverse effects. (F)
324002
Recommendation Grading
Overview
Title
Responsible Opioid Prescribing In Chronic Non-Cancer Pain: Part 2 - Guidance
Authoring Organization
American Society of Interventional Pain Physicians
Publication Month/Year
July 1, 2012
Last Updated Month/Year
January 8, 2024
Document Type
Guideline
External Publication Status
Published
Country of Publication
US
Document Objectives
Guidelines on responsible opioid prescribing provides the recommendations for initiating and maintaining chronic opioid therapy of 90 days or longer.
Target Patient Population
Patient with chronic pain
Inclusion Criteria
Male, Female, Adolescent, Adult, Child, Older adult
Health Care Settings
Ambulatory, Hospice, Hospital, Long term care, Outpatient
Intended Users
Nurse, nurse practitioner, physician, physician assistant
Scope
Counseling, Diagnosis, Assessment and screening, Treatment, Management
Diseases/Conditions (MeSH)
D059350 - Chronic Pain, D059408 - Pain Management, D000701 - Analgesics, Opioid, D009293 - Opioid-Related Disorders
Keywords
opioids, chronic pain, Opioid Use Disorder
Source Citation
Pain Physician 2012; 15:S67-S116